SCHEMBL257524

SCHEMBL257524

Cc1ccc(NS(=O)(=O)C2CC2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 2/20 0.53
CA2 P00918 2/20 0.53
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
HPGD P15428 1/20 0.50
BRPF1 P55201 1/20 0.48
MAPT P10636 4/20 0.47
ALDH1A1 P00352 3/20 0.47
LMNA P02545 1/20 0.47
TP53 P04637 1/20 0.47
ATM Q13315 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
FKBP1A P62942 1/20 0.47
HDAC4 P56524 1/20 0.47
HRH3 Q9Y5N1 1/20 0.45
SGK1 O00141 1/20 0.44
RECQL P46063 1/20 0.44
PGR P06401 1/20 0.44
CA12 O43570 1/20 0.43
CA9 Q16790 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4319262 0.91 ALDH1A1 (0.55) CA1CA2MEN1KMT2AHPGD
SCHEMBL3088517 0.80 SGK1 (0.51) CA1CA2MEN1KMT2ABRPF1
SCHEMBL21590270 0.80 CA1 (0.53) CA1CA2BRPF1FKBP1AHDAC4
SCHEMBL28207342 0.80 HDAC4 (0.47) BRPF1HDAC4HRH3SGK1CYP17A1
SCHEMBL3980159 0.80 CA1 (0.53) CA1CA2HPGDBRPF1ALDH1A1
SCHEMBL14830078 0.80 MAP2K4 (0.56) CA1CA2MEN1KMT2ABRPF1
SCHEMBL18953568 0.79 HDAC4 (0.54) BRPF1HDAC4HRH3SGK1MAP2K4
SCHEMBL15614453 0.79 PGR (0.49) MEN1KMT2ABRPF1MAPTALDH1A1
SCHEMBL17450352 0.79 HPGD (0.54) MEN1KMT2AHPGDBRPF1MAPT
SCHEMBL6850398 0.79 HDAC4 (0.56) CA1CA2MEN1KMT2ABRPF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3793990-B1 ANTIBACTERIAL COMPOUNDS INFEX THERAPEUTICS LTD (GB) 2023-07-19 EP disclosed
US-20230157996-A1 SMALL-MOLECULE INHIBITOR TARGETING EB VIRUS NUCLEAR ANTIGEN PROTEIN, PREPARATION METHOD AND USE THEREOF Shenzhen Bay Laboratory (CN) 2023-05-25 US disclosed
US-20230157996-A1 SMALL-MOLECULE INHIBITOR TARGETING EB VIRUS NUCLEAR ANTIGEN PROTEIN, PREPARATION METHOD AND USE THEREOF Shenzhen Bay Laboratory (CN) 2023-05-25 US disclosed
EP-3169662-B1 SUBSTITUTED VINYL- AND ALKINYL-CYANOCYCLOALKANOLS AND VINYL- AND ALKINYL-CYANOHETEROCYCLOALKANOLS AS AGENTS TO COMBAT ABIOTIC PLANT STRESS BAYER CROPSCIENCE AG (DE) 2018-07-11 EP disclosed
US-9226505-B2 4-substituted 1-phenylpyrazole-3-carboxylic acid derivatives as agents against abiotic plant stress BAYER INTELLECTUAL PROPERTY GMBH (DE) 2016-01-05 US disclosed
US-8975264-B2 Compound acting as a cannabinoid receptor-1 inhibitor AMOREPACIFIC CORPORATION (KR) 2015-03-10 US disclosed
US-20140329684-A1 USE OF 4-SUBSTITUTED 1-PHENYLPYRAZOLE-3-CARBOXYLIC ACID DERIVATIVES AS AGENTS AGAINST ABIOTIC PLANT STRESS BAYER INTELLECTUAL PROPERTY GMBH (DE) 2014-11-06 US disclosed
US-20130158025-A1 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR AMOREPACIFIC CORPORATION (KR) 2013-06-20 US disclosed
WO-2013041602-A1 USE OF 4-SUBSTITUTED 1-PHENYL-PYRAZOLE-3-CARBOXYLIC-ACID DERIVATIVES AS AGENTS AGAINST ABIOTIC PLANT STRESS BAYER INTELLECTUAL PROPERTY GMBH (DE) 2013-03-28 WO disclosed
EP-2510786-A1 Substituted Prop-2-in-1-ol and Prop-2-en-1-ol derivatives Bayer CropScience AG (DE) 2012-10-17 EP disclosed
US-20100292187-A1 METHODS FOR TREATING HEPATITIS C PTC THERAPEUTICS, INC. (US) 2010-11-18 US disclosed
WO-2009058919-A1 CCR5 ANTAGONISTS AS THERAPEUTIC AGENTS SMITHKLINE BEECHAM CORPORATION (US) 2009-05-07 WO disclosed
US-20090029982-A1 PROTEIN KINASE INHIBITORS SUPERGEN, INC. (US) 2009-01-29 US disclosed
US-20090029982-A1 PROTEIN KINASE INHIBITORS SUPERGEN, INC. (US) 2009-01-29 US disclosed
US-20080207632-A1 PROTEIN KINASE INHIBITORS SUPERGEN, INC. (US) 2008-08-28 US disclosed
US-20080207632-A1 PROTEIN KINASE INHIBITORS SUPERGEN, INC. (US) 2008-08-28 US disclosed
WO-2008055233-A1 PROTEIN KINASE INHIBITORS SUPERGEN, INC. (US) 2008-05-08 WO disclosed
US-20080096928-A9 Indole compounds that modify translational control of Hepatitis C virus PTC THERAPEUTICS, INC. 2008-04-24 US disclosed
WO-2007084413-A2 METHODS FOR TREATING HEPATITIS C PTC THERAPEUTICS, INC. (US) 2007-07-26 WO disclosed
WO-2007084435-A2 METHODS FOR TREATING HEPATITIS C PTC THERAPEUTICS, INC. (US) 2007-07-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140329684-A1 USE OF 4-SUBSTITUTED 1-PHENYLPYRAZOLE-3-CARBOXYLIC ACID DERIVATIVES AS AGENTS AGAINST ABIOTIC PLANT STRESS HPD, HSF1, PDK4 CA1 2218/4885CA2 381/4885MEN1 4843/4885
US-20080096928-A9 Indole compounds that modify translational control of Hepatitis C virus EIF2AK2, INMT, IDO1 CA1 4603/4885CA2 4565/4885MEN1 4550/4885
US-20230157996-A1 SMALL-MOLECULE INHIBITOR TARGETING EB VIRUS NUCLEAR ANTIGEN PROTEIN, PREPARATION METHOD AND USE THEREOF SSB, EBNA1BP2, PML CA1 3957/4885CA2 4318/4885MEN1 763/4885
US-20080207632-A1 PROTEIN KINASE INHIBITORS ERBB3, ERBB2, AXL CA1 3473/4885CA2 1825/4885MEN1 1002/4885
US-20090029982-A1 PROTEIN KINASE INHIBITORS CDK2, PACSIN2, AKT1 CA1 4036/4885CA2 1957/4885MEN1 1439/4885
US-20100292187-A1 METHODS FOR TREATING HEPATITIS C HAVCR2, EIF2AK2, MAVS CA1 1456/4885CA2 1877/4885MEN1 4800/4885
US-20130158025-A1 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR CNR1, CNR2, GPR18 CA1 1254/4885CA2 1775/4885MEN1 3752/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.